Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...

Roche Holding AG said side effects in a highly anticipated study of its experimental obesity pill were milder when it eased ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Roche Holding AG’s shares slid the most in more than a month after its closely-watched experimental obesity pill was tied to ...

Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

Roche's experimental weight-loss pill, CT-996, showed promising early-stage trial results, causing shares to rise. However, ...

Shares in Roche fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a ...

Roche shares were trading 3.5% down by 0940 GMT, the second biggest faller on the pan-European STOXX 600 index, after the company presented details on the trial with once-daily pill CT-996 late on ...

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health market with acquisition of Veri.

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders ...